Harpoon Therapeutics Provides an Update on the HPN217 Development and Option Agreement with AbbVie
14 9월 2023 - 5:05AM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immuno-oncology company developing novel T cell engagers, announced
today that AbbVie has notified the company that it will not
exercise the exclusive license option of the parties’ Development
and Option Agreement in connection with Harpoon’s HPN217
program, which targets B cell maturation antigen, or
BCMA. The Agreement, which will terminate effective October
12, 2023, granted AbbVie an option to a worldwide, exclusive
license to the HPN217 program. The program has been and will
remain exclusively owned by Harpoon, and the company plans to
complete the ongoing Phase 1 clinical trial with data to support
the next phase of development.
“There is a significant unmet medical need for patients living
with advanced multiple myeloma who have progressed after prior
treatments, including patients with prior BCMA-targeted therapies,
and we remain confident in HPN217’s potential to offer these
patients a differentiated treatment option,” said Julie Eastland,
President and CEO of Harpoon Therapeutics. “We will share
interim results with the scientific community at the upcoming IMS
meeting. The preliminary data from the HPN217 study continue to be
encouraging with a favorable safety profile.”
Harpoon previously announced abstract acceptance and a poster
presentation of preliminary data up to and including 12 mg cohorts
from the dose escalation portion of the Phase 1 study of HPN217 in
patients with relapsed/refractory multiple myeloma. The
presentation will take place on September 28, 2023 at the 20th
International Myeloma Society (IMS) Annual Meeting being held in
Athens, Greece.
Harpoon continues to be committed to advancing its T cell
engager pipeline, including HPN328, DLL3 targeting TriTAC® and
HPN601, an EpCAM targeting ProTriTAC™, and plans to present the
interim Phase 1/2 clinical data from HPN328 at European Society for
Medical Oncology (ESMO) being held on October 20-24, 2023.
About Harpoon Therapeutics Harpoon
Therapeutics is a clinical-stage immuno-oncology company
developing a novel class of T cell engagers that harness the power
of the body’s immune system to treat patients suffering from cancer
and other diseases. T cell engagers are engineered proteins that
direct a patient’s own T cells to kill target cells that express
specific proteins, or antigens, carried by the target cells. Using
its proprietary Tri-specific T cell Activating Construct (TriTAC®)
platform, Harpoon is developing a pipeline of novel
TriTACs initially focused on the treatment of solid tumors and
hematologic malignancies. Harpoon has also developed a proprietary
ProTriTAC™ platform, which applies a prodrug concept to its
TriTAC platform to create a therapeutic T cell engager that
remains inactive until it reaches the tumor. Harpoon’s third
proprietary technology platform, extended release TriTAC-XR, is
designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as “continue,” “plan,” “will,” and
similar expressions (as well as other words or expressions
referencing future events, conditions or circumstances) are
intended to identify forward-looking statements. Forward-looking
statements contained in this press release include, but are not
limited to, statements relating to Harpoon’s plans to complete the
ongoing Phase 1 clinical trial, the therapeutic potential of
HPN217, plans concerning advancement of Harpoon’s pipeline, data
presentation plans and other statements that are not historical
fact. These forward-looking statements are based on Harpoon
Therapeutics’ expectations and assumptions as of the date of this
press release. Each of these forward-looking statements involves
risks and uncertainties that could cause Harpoon Therapeutics’
clinical development programs, future results or performance to
differ significantly from those expressed or implied by the
forward-looking statements. These and other factors that may cause
Harpoon Therapeutics’ actual results to differ from those expressed
or implied in the forward-looking statements in this press release
are discussed in Harpoon Therapeutics’ filings with the U.S.
Securities and Exchange Commission, including under “Risk Factors”
in Harpoon Therapeutics’ quarterly report on Form 10-Q for the
quarter ended June 30, 2023, and future filings
by Harpoon Therapeutics. Except as required by
law, Harpoon Therapeutics assumes no obligation to update
any forward-looking statements contained herein to reflect any
change in expectations, even as new information becomes
available.
Harpoon ContactInvestors and Media:ICR
WestwickeRobert H. UhlManaging Director858-356-5932
robert.uhl@westwicke.com
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Harpoon Therapeutics (NASDAQ:HARP)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024